JP2006500016A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006500016A5 JP2006500016A5 JP2004532837A JP2004532837A JP2006500016A5 JP 2006500016 A5 JP2006500016 A5 JP 2006500016A5 JP 2004532837 A JP2004532837 A JP 2004532837A JP 2004532837 A JP2004532837 A JP 2004532837A JP 2006500016 A5 JP2006500016 A5 JP 2006500016A5
- Authority
- JP
- Japan
- Prior art keywords
- allele
- fibrostenosis
- disease
- predisposing
- nod2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108700028369 Alleles Proteins 0.000 claims description 39
- 238000000034 method Methods 0.000 claims description 30
- 102100029441 Nucleotide-binding oligomerization domain-containing protein 2 Human genes 0.000 claims description 25
- 101001125026 Homo sapiens Nucleotide-binding oligomerization domain-containing protein 2 Proteins 0.000 claims description 17
- 108700002045 Nod2 Signaling Adaptor Proteins 0.000 claims description 17
- 101150083031 Nod2 gene Proteins 0.000 claims description 13
- 208000031481 Pathologic Constriction Diseases 0.000 claims description 11
- 208000037804 stenosis Diseases 0.000 claims description 11
- 230000036262 stenosis Effects 0.000 claims description 11
- 208000011231 Crohn disease Diseases 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 230000003176 fibrotic effect Effects 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 5
- 238000012408 PCR amplification Methods 0.000 claims 3
- 238000003745 diagnosis Methods 0.000 claims 3
- 230000003321 amplification Effects 0.000 claims 2
- 238000003199 nucleic acid amplification method Methods 0.000 claims 2
- 230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 claims 2
- 239000000523 sample Substances 0.000 claims 2
- 108091026890 Coding region Proteins 0.000 claims 1
- 108020004414 DNA Proteins 0.000 claims 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 claims 1
- 108091092724 Noncoding DNA Proteins 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 230000002255 enzymatic effect Effects 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 238000005457 optimization Methods 0.000 claims 1
- 102000050697 Nod2 Signaling Adaptor Human genes 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 3
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 102200146596 rs2066845 Human genes 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 1
- 108010006444 Leucine-Rich Repeat Proteins Proteins 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 210000004901 leucine-rich repeat Anatomy 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40739102P | 2002-08-30 | 2002-08-30 | |
| US10/356,736 US20040053263A1 (en) | 2002-08-30 | 2003-01-30 | Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease |
| PCT/US2003/023926 WO2004020968A2 (en) | 2002-08-30 | 2003-07-30 | Mutations in nod2 are associated with fibrostenosing disease in patients with crohn’s disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010174021A Division JP2011015686A (ja) | 2002-08-30 | 2010-08-02 | Ｎｏｄ２における変異は、クローン病を有する患者における線維性狭窄疾患に関連する |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006500016A JP2006500016A (ja) | 2006-01-05 |
| JP2006500016A5 true JP2006500016A5 (enExample) | 2006-09-14 |
| JP4606877B2 JP4606877B2 (ja) | 2011-01-05 |
Family
ID=31981139
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004532837A Expired - Fee Related JP4606877B2 (ja) | 2002-08-30 | 2003-07-30 | Ｎｏｄ２における変異は、クローン病を有する患者における線維性狭窄疾患に関連する |
| JP2010174021A Withdrawn JP2011015686A (ja) | 2002-08-30 | 2010-08-02 | Ｎｏｄ２における変異は、クローン病を有する患者における線維性狭窄疾患に関連する |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010174021A Withdrawn JP2011015686A (ja) | 2002-08-30 | 2010-08-02 | Ｎｏｄ２における変異は、クローン病を有する患者における線維性狭窄疾患に関連する |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20040053263A1 (enExample) |
| EP (1) | EP1556405B1 (enExample) |
| JP (2) | JP4606877B2 (enExample) |
| AT (1) | ATE462710T1 (enExample) |
| AU (1) | AU2003263834A1 (enExample) |
| DE (1) | DE60331941D1 (enExample) |
| WO (1) | WO2004020968A2 (enExample) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6828132B2 (en) * | 2001-03-01 | 2004-12-07 | Ultra Biotech Limited | Biological fertilizer compositions comprising garbage |
| US20040053263A1 (en) * | 2002-08-30 | 2004-03-18 | Abreu Maria T. | Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease |
| US7662569B2 (en) * | 2003-04-11 | 2010-02-16 | Cedars-Sinai Medical Center | Methods of assessing Crohn's disease patient phenotype by I2 serologic response |
| US7592150B2 (en) * | 2003-12-03 | 2009-09-22 | Glycominds, Ltd | Method for diagnosing diseases based on levels of anti-glycan antibodies |
| WO2005054853A2 (en) * | 2003-12-03 | 2005-06-16 | Glycominds, Ltd | Method for diagnosing diseases based on levels of anti-glycan antibodies |
| US20060205022A1 (en) * | 2003-12-03 | 2006-09-14 | Nir Dotan | Method for diagnosing and prognosing inflammatory bowel disease and crohn's disease |
| SI1730315T1 (sl) * | 2004-03-27 | 2010-02-26 | Klein Hanns Georg | Polimorfizmi v genu NOD2/CARD15 |
| WO2005115135A2 (en) * | 2004-04-09 | 2005-12-08 | The Regents Of The University Of California | Mouse model of crohn’s disease and a method to develop specific therapeutics |
| WO2008109782A2 (en) * | 2007-03-06 | 2008-09-12 | Cedars-Sinai Medical Center | Diagnosis of inflammatory bowel disease in children |
| US11268149B2 (en) | 2004-12-08 | 2022-03-08 | Cedars-Sinai Medical Center | Diagnosis and treatment of inflammatory bowel disease |
| US10544459B2 (en) * | 2004-12-08 | 2020-01-28 | Cedars-Sinai Medical Center | Methods of using genetic variants for the diagnosis and treatment of inflammatory bowel disease |
| US12110555B2 (en) | 2004-12-08 | 2024-10-08 | Cedars-Sinai Medical Center | Diagnosis and treatment of inflammatory bowel disease |
| WO2008101133A2 (en) * | 2007-02-14 | 2008-08-21 | Cedars-Sinai Medical Center | Methods of using genes and genetic variants to predict or diagnose inflammatory bowel disease |
| AU2005314089B2 (en) * | 2004-12-08 | 2011-03-03 | Cedars-Sinai Medical Center | Methods for diagnosis and treatment of Crohn's disease |
| WO2008014400A2 (en) * | 2006-07-26 | 2008-01-31 | Genizon Biosciences Inc. | Crohn disease susceptibility gene |
| US20080131887A1 (en) | 2006-11-30 | 2008-06-05 | Stephan Dietrich A | Genetic Analysis Systems and Methods |
| EP2102651A4 (en) * | 2006-11-30 | 2010-11-17 | Navigenics Inc | GENERALYSIS SYSTEMS AND METHODS |
| US20100190162A1 (en) * | 2007-02-26 | 2010-07-29 | Cedars-Sinai Medical Center | Methods of using single nucleotide polymorphisms in the tl1a gene to predict or diagnose inflammatory bowel disease |
| US8486640B2 (en) | 2007-03-21 | 2013-07-16 | Cedars-Sinai Medical Center | Ileal pouch-anal anastomosis (IPAA) factors in the treatment of inflammatory bowel disease |
| WO2008134569A2 (en) * | 2007-04-26 | 2008-11-06 | Cedars-Sinai Medical Center | Diagnosis and treatment of inflammatory bowel disease in the puerto rican population |
| US20100144903A1 (en) * | 2007-05-04 | 2010-06-10 | Cedars-Sinai Medical Center | Methods of diagnosis and treatment of crohn's disease |
| WO2012135144A2 (en) * | 2011-03-25 | 2012-10-04 | Cedars-Sinai Medical Center | Methods of diagnosing and treating intestinal granulomas and low bone density in inflammatory bowel disease |
| WO2009069007A2 (en) * | 2007-11-30 | 2009-06-04 | Glycominds, Ltd. | Composition and method for prediction of complicated disease course and surgeries in crohn's disease |
| WO2009143278A2 (en) * | 2008-05-20 | 2009-11-26 | Cedars-Sinai Medical Center | Methods of diagnosing and characterizing cannabinoid signaling in crohn's disease |
| US20110177969A1 (en) * | 2008-10-01 | 2011-07-21 | Cedars-Sinai Medical Center | The role of il17rd and the il23-1l17 pathway in crohn's disease |
| US20110189685A1 (en) * | 2008-10-22 | 2011-08-04 | Cedars-Sinai Medical Center | Methods of using jak3 genetic variants to diagnose and predict crohn's disease |
| WO2010062960A2 (en) | 2008-11-26 | 2010-06-03 | Cedars-Sinai Medical Center | METHODS OF DETERMINING RESPONSIVENESS TO ANTI-TNFα THERAPY IN INFLAMMATORY BOWEL DISEASE |
| US9580752B2 (en) | 2008-12-24 | 2017-02-28 | Cedars-Sinai Medical Center | Methods of predicting medically refractive ulcerative colitis (MR-UC) requiring colectomy |
| EP2960342A1 (en) | 2009-04-14 | 2015-12-30 | Nestec S.A. | Inflammatory bowel disease prognostics |
| WO2011060098A1 (en) | 2009-11-10 | 2011-05-19 | Prometheus Laboratories Inc. | Methods for predicting post-surgery risk associated with ileal pouch-anal anastomosis |
| WO2011088306A1 (en) * | 2010-01-15 | 2011-07-21 | Cedars-Sinai Medical Center | Methods of using genetic variants to diagnose crohn's disease |
| JP5960707B2 (ja) | 2010-10-18 | 2016-08-02 | ネステク ソシエテ アノニム | 抗薬物抗体アイソタイプを決定するための方法 |
| ES2530175T3 (es) | 2011-02-17 | 2015-02-26 | Nestec S.A. | Ensayos para la detección de autoanticuerpos contra fármacos anti-TNF |
| CN110544517A (zh) | 2011-05-10 | 2019-12-06 | 雀巢产品有限公司 | 用于个体化治疗管理的疾病活动性表征方法 |
| EP2769321B1 (en) | 2011-10-21 | 2016-06-01 | Nestec S.A. | Methods for improving inflammatory bowel disease diagnosis |
| US10633449B2 (en) | 2013-03-27 | 2020-04-28 | Cedars-Sinai Medical Center | Treatment and reversal of fibrosis and inflammation by inhibition of the TL1A-DR3 signaling pathway |
| JP2016522679A (ja) | 2013-04-04 | 2016-08-04 | プレジデント アンド フェローズ オブ ハーバード カレッジ | ＣＲＩＳＰＲ／Ｃａｓ系を用いたゲノム編集の治療的使用 |
| EP3022295A4 (en) | 2013-07-19 | 2017-03-01 | Cedars-Sinai Medical Center | Signature of tl1a (tnfsf15) signaling pathway |
| EP4269601A3 (en) | 2015-03-27 | 2024-01-10 | President and Fellows of Harvard College | Modified t cells and methods of making and using the same |
| WO2017161342A1 (en) | 2016-03-17 | 2017-09-21 | Cedars-Sinai Medical Center | Methods of diagnosing inflammatory bowel disease through rnaset2 |
| WO2018195129A1 (en) | 2017-04-17 | 2018-10-25 | University Of Maryland, College Park | Embryonic cell cultures and methods of using the same |
| CA3124970A1 (en) * | 2018-12-28 | 2020-07-02 | Cedars-Sinai Medical Center | Methods of treating inflammatory bowel diseases that target ripk2 |
| US20220370509A1 (en) * | 2019-11-12 | 2022-11-24 | Orchard Therapeutics (Europe) Limited | Compositions and methods for treating or preventing crohn's disease |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3157053B2 (ja) * | 1992-09-16 | 2001-04-16 | ティーディーケイ株式会社 | Ｄｎａ作用物質の結合様式特定方法 |
| US5830675A (en) * | 1993-03-10 | 1998-11-03 | Cedars-Sinai Medical Center | Methods for selectively detecting perinuclear anti-neutrophil cytoplasmic antibody of ulcerative colitis, primary sclerosing cholangitis, or type 1 autoimmune hepatitis |
| ES2148251T3 (es) * | 1993-03-10 | 2000-10-16 | Cedars Sinai Medical Center | Metodos para detectar selectivamente anticuerpos anticitoplasma de neutrofilos perinucleares de la colitis ulcerosa o colangitis esclerosante primaria. |
| US5691151A (en) * | 1994-10-07 | 1997-11-25 | Regents Of University Of California | Methods of screening for ulcerative colitis and crohn's disease by detecting VH3-15 autoantibody and panca |
| US5916748A (en) * | 1996-04-12 | 1999-06-29 | Cedars-Sinai Medical Center | Method of diagnosing a clinical subtype of crohn's disease with features of ulcerative colitis |
| US5874233A (en) * | 1996-04-12 | 1999-02-23 | Cedars-Sinai Medical Center | Methods of diagnosing a clinical subtype of Crohn's disease with features of ulcerative colitis |
| AU2438397A (en) * | 1996-04-12 | 1997-11-07 | Cedars-Sinai Medical Center | Methods of determining the risk of pouchitis development |
| US6074835A (en) * | 1996-04-12 | 2000-06-13 | Regents Of The Univ. Of California | Diagnosis, prevention and treatment of ulcerative colitis, and clinical subtypes thereof, using histone H1 |
| US5968741A (en) * | 1997-04-11 | 1999-10-19 | Cedars-Sinai Medical Center | Methods of diagnosing a medically resistant clinical subtype of ulcerative colitis |
| US6514700B1 (en) * | 1999-04-30 | 2003-02-04 | Aclara Biosciences, Inc. | Nucleic acid detection using degradation of a tagged sequence |
| JP2001269196A (ja) * | 2000-03-24 | 2001-10-02 | Hamamatsu Photonics Kk | 被検体核酸の定量方法、および被検体核酸の分子数の計数方法 |
| US7138237B1 (en) * | 2000-05-19 | 2006-11-21 | Cedars-Sinai Medical Center | Diagnosis, prevention and treatment of Crohn's disease using the OmpC antigen |
| US20030092019A1 (en) * | 2001-01-09 | 2003-05-15 | Millennium Pharmaceuticals, Inc. | Methods and compositions for diagnosing and treating neuropsychiatric disorders such as schizophrenia |
| US20040053263A1 (en) * | 2002-08-30 | 2004-03-18 | Abreu Maria T. | Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease |
-
2003
- 2003-01-30 US US10/356,736 patent/US20040053263A1/en not_active Abandoned
- 2003-07-30 AU AU2003263834A patent/AU2003263834A1/en not_active Abandoned
- 2003-07-30 WO PCT/US2003/023926 patent/WO2004020968A2/en not_active Ceased
- 2003-07-30 EP EP03791618A patent/EP1556405B1/en not_active Expired - Lifetime
- 2003-07-30 JP JP2004532837A patent/JP4606877B2/ja not_active Expired - Fee Related
- 2003-07-30 AT AT03791618T patent/ATE462710T1/de not_active IP Right Cessation
- 2003-07-30 DE DE60331941T patent/DE60331941D1/de not_active Expired - Lifetime
- 2003-07-30 US US10/526,256 patent/US7790370B2/en not_active Expired - Lifetime
-
2010
- 2010-08-02 JP JP2010174021A patent/JP2011015686A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006500016A5 (enExample) | ||
| Li et al. | A human-specific de novo protein-coding gene associated with human brain functions | |
| EP1649061B1 (en) | Genes as diagnostic tools for autism | |
| Jeschke et al. | A high risk phenotype of hypertrophic cardiomyopathy associated with a compound genotype of two mutated β-myosin heavy chain genes | |
| JP2014533949A5 (enExample) | ||
| CA2511042A1 (en) | Association of single nucleotide polymorphisms in ppar.gamma. with osteoporosis | |
| ElSharawy et al. | Accurate variant detection across non-amplified and whole genome amplified DNA using targeted next generation sequencing | |
| Paperna et al. | Genes for the CPE receptor (CPETR1) and the human homolog of RVP1 (CPETR2) are localized within the Williams–Beuren syndrome deletion | |
| AU2020225197B2 (en) | Piezo type mechanosensitive ion channel component 1 (PIEZO1) variants and uses thereof | |
| JP2007209354A (ja) | 塩基変異分析方法 | |
| EP3453760B1 (en) | Prediction of hepatocellular carcinoma onset after clearance of hepatitis c virus | |
| TWI579722B (zh) | 藥物不良反應風險評估方法及其裝置 | |
| KR102095017B1 (ko) | Col6a6 유전자 단일염기다형성을 이용한 아토피 피부염 진단용 조성물과 검출 방법 | |
| US20080020383A1 (en) | Haplotype Markers And Methods Of Using The Same To Determine Response To Treatment | |
| US20140271542A1 (en) | Genetic marker for predicting prognosis in patients infected with hepatitis c virus | |
| JP4150057B2 (ja) | 疾患に関連する核酸を検出する方法 | |
| KR20070004082A (ko) | Ｆｃ 수용체 다형성의 확인을 위한 핵산 기반 분석 | |
| KR101791246B1 (ko) | 크론병의 임상적 특성의 예측 방법 | |
| KR101598296B1 (ko) | Dna 복제수 변이를 이용한 강직성 척추염 발병 고위험도 예측용 조성물 및 이를 이용한 예측 방법 | |
| WO2004003229A2 (en) | Disease risk estimating method using sequence polymorphisms in a specific region of chromosome 19 | |
| JP5656159B2 (ja) | インターフェロン療法の効果予測用マーカー | |
| JP6516128B2 (ja) | 抗甲状腺薬誘発性無顆粒球症リスクを判定するための検査方法及び判定用キット | |
| WO2010040365A1 (en) | Method for identifying an increased susceptibility to ulcerative colitis | |
| KR102106807B1 (ko) | 당뇨 망막증 진단용 마커 및 이의 용도 | |
| JP2007512231A5 (enExample) |